Past participating companies have raised more than $675 million
DURHAM, N.C., March 22, 2016 – Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to participate at the 3 Rivers Venture Fair (3VRF) and Venture Connection, being held April 5-6, 2016 at The David L. Lawrence Convention Center in Pittsburgh.
“The technology platform of Arcato Laboratories is based upon a patented method of delivering a local anesthetic to oral mucosal membranes over a sustained period of time,” said Meldrum. “The Arcato technology platform has many applications for other types of pain relief, but the OraWax™ product alone has an estimated market of about $400 million per year,” he added.
Since the Fair’s debut in 2002, the cornerstone of the event has been the company presentations – where capital-raising entrepreneurs were given eight minutes to pitch their investment prospects to attending venture capitalists and private investors. This year, 3VRF is doing away with the presentations in favor of a format called Venture Connection. Investors will host tables to meet with groups of entrepreneurs that have been matched with them based on capital needs, industry and other key criteria.
Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.
About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). For more information on investing, please visit our Investor Relations Page.